The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease
Open accessAbstract
SUMMARY Self-reactive IgGs contribute to the pathology of autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. Paradoxically, IgGs are used to treat inflammatory diseases, in the form of high-dose intravenous immunoglobulin (IVIG). Distinct glycoforms on the IgG constant fragment (Fc) dictate these divergent functions. IgG anti-inflammatory activity is attributed to sialylation of the Fc glycan. We therefore sought to convert endogenous IgG to anti-inflammatory mediators in vivo by engineering solubilized glycosyltransferases that attach galactose or sialic acid. When both enzymes were administered in a prophylactic or therapeutic fashion, autoimmune inflammation was markedly attenuated in vivo. The enzymes worked through a similar pathway to IVIG, requiring DC-SIGN, STAT6 signaling, and FcγRIIB. Importantly, sialylation was highly specific to pathogenic IgG at the site of inflammation, driven by local platelet release of nucleotide-sugar donors. These results underscore the therapeutic potential of glycoengineering in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 2×
“They are essential for clearance of microbes by bridging the adaptive and innate immune systems, but they can also contribute to the pathogenesis of autoimmune diseases when they are generated against self (Nimmerjahn and Ravetch, 2008b).”
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849
Self-citationGlycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 1×
“Studies over the last decade have demonstrated the composition of the Fc glycan exerts profound influence over IgG effector functions (Jefferis, 2005, 2009a, 2009b).”
Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770
Schlothauer, T., Herter, S., Koller, C. F., Grau-Richards, S., Steinhart, V., Spick, C., Kubbies, M., Klein, C., Umaña, P., & Mössner, E. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw040 · Cited by 425 · cited 1×
“Also, these glycosyltransferases could be further engineered, including increased FcRn affinity to extend serum half-life or increased/decreased receptor binding (Schlothauer et al., 2016).”
Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura
Debré, M., Griscelli, C., Bonnet, M.-C., Carosella, E., Philippe, N., Reinert, P., Vilmer, E., Kaplan, C., Fridman, W. H., & Teillaud, J.-L. (1993) · The Lancet · doi:10.1016/0140-6736(93)92000-j · Cited by 329
Davies, J., Jiang, L., Pan, L., LaBarre, M. J., Anderson, D., & Reff, M. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1119 · Cited by 327
Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury
Zhang, G., Massaad, C. A., Gao, T., Pillai, L., Bogdanova, N., Ghauri, S., & Sheikh, K. A. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.05.020 · Cited by 38 · cited 2×
“10 Cell 172, 1–14, January 25, 2018 IVIG anti-inflammatory activity in vivo (Fiebiger et al., 2015; Kaneko et al., 2006b; Ohmi et al., 2016; Schwab et al., 2012; Schwab et al., 2014; Washburn et al., 2015; Zhang et al., 2016).”
Cited by
Glycosylation in health and disease
Reily, C., Stewart, T. J., Renfrow, M. B., & Novak, J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0129-4 · Cited by 2,075
Structures and General Transport Mechanisms by the Major Facilitator Superfamily (MFS)
Drew, D., North, R. A., Nagarathinam, K., & Tanabe, M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00983 · Cited by 465
Immunoglobulin G glycosylation in aging and diseases
Gudelj, I., Lauc, G., & Pezer, M. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.07.009 · Cited by 408
Exploration of the Sialic Acid World
(2018) · Advances in Carbohydrate Chemistry and Biochemistry · doi:10.1016/bs.accb.2018.09.001 · Cited by 320
Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800896 · Cited by 82
Contribution of gut microbiota toward renal function in sepsis
Xu, Y., Kong, X., Zhu, Y., Xu, J., Mao, H., Li, J., Zhang, J., & Zhu, X. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.985283 · Cited by 22
Blundell, P. A., Lu, D., Wilkinson, M., Dell, A., Haslam, S., & Pleass, R. J. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801337 · Cited by 11
Metadata
- Authors
- Pagan, J. D., Kitaoka, M., & Anthony, R. M.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 172
- Issue
- 3
- Pages
- 564-577.e13
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2778963731
- Cited by
- 204
- References
- 10
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.